IP Library Granted Patent US 9,375,454
Granted Patent B2
US 9,375,454 · App. 13/319,627 · Granted Jun 28, 2016

Infant feeding formulas comprising probiotic micro-organisms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,375,454
App. No.
13/319,627
Granted
Jun 28, 2016
Kind
B2
Abstract

The present invention relates to the field of infant nutrition. In particular, the present invention relates to infant feeding formulas comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Claims (15)

1. An infant feeding formula to be administered to infants as an only nutrition source or as a complementary nutrition source in addition to breastfeeding, to provide complete nutrition to the infant and also comprising non-replicating probiotic micro-organisms rendered non-replicating by a heat treatment at 120 to 140° C. for 5-15 seconds, the non-replicating probiotic micro-organisms selected from the group consisting of Bifidobacterium longum NCC 2705, Bifidobacterium breve NCC 2950, Lactobacillus johnsonii La1 , Lactobacillus reuteri DSM17938, Lactobacillus reuteri ATCC55730, Streptococcus thermophilus NCC 2019, Streptococcus thermophilus NCC 2059, Lactobacillus casei NCC 4006, Lactobacillus acidophilus NCC 3009, Lactobacillus casei ACA-DC 6002 (NCC 1825), Escherichia coli Nissle, Lactobacillus bulgaricus NCC 15, Lactococcus lactis NCC 2287, and combinations thereof, wherein the non-replicating probiotic micro-organisms induce less pro-inflammatory cytokines while maintaining or inducing additional Interleukin 10 (IL-10) production relative to live counterpart.

2. The infant feeding formula in accordance with claim 1 having a caloric density of 62-68 kcal/100 ml, and comprising a protein source in an amount of 1.5-2.8 g/100 kcal, a carbohydrate source in an amount of 10-12 g/100 kcal, and a lipid source in an amount of 5-5.5 g/100 kcal.

3. The infant feeding formula in accordance with claim 1 , comprising 0.2-0.3 g LC-PUFA/100 g fatty acids, wherein the LC-PUFA are a combination of ARA and DHA.

4. The infant feeding formula in accordance with claim 1 , comprising 1.5-2.5 mg nucleotides per 100 mL formula.

5. The infant feeding formula in accordance with claim 1 , comprising the non-replicating probiotic micro-organisms in an amount corresponding to 10 4 to 10 12 cfu.

6. A method for the treatment of inflammatory disorders, the method comprising:

administering to an infant the infant feeding formula of claim 1 .

7. A method for the treatment of disorders related to a compromised immune defense, the method comprising:

administering to an infant the infant feeding formula of claim 1 .

8. The infant feeding formula in accordance with claim 1 further comprising a live counterpart of the non-replicating probiotic micro-organisms.

9. The infant feeding formula in accordance with claim 1 , containing about 0.005 mg-1000 mg of the non: replicating micro-organisms per daily dose.

10. The method in accordance with claim 6 , wherein the infant formula has a caloric density in the range of 62-68 kcal/100 ml and further comprises a protein source in an amount of 1.5-2.8 g/100 kcal, a carbohydrate source in an amount of 10-12 g/100 kcal, and a lipid source in an amount of 5-5.5 g/100 kcal.

11. The method in accordance with claim 6 , wherein the infant formula comprises about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.

12. The method in accordance with claim 7 , wherein the infant formula has a caloric density in the range of 62-68 kcal/100 ml and further comprises a protein source in an amount of 1.5-2.8 g/100 kcal, a carbohydrate source in an amount of 10-12 g/100 kcal, and a lipid source in an amount of 5-5.5 g/100 kcal.

13. The method in accordance with claim 7 , wherein the infant formula comprises about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2012
From: MERCENIER, ANNICK; NUTTEN, SOPHIE; PRIOULT, GUENOLEE
To: NESTEC S.A.
Reel/Frame 027522/0338 →